Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 6/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.35 |
| ▸ | DDR1 | Q08345 | 3/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.33 |
| ▸ | PLG | P00747 | 1/20 | 0.33 |
| ▸ | PROC | P04070 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.33 |
| ▸ | F7 | P08709 | 1/20 | 0.33 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6941228 | 0.97 | F10 (0.35) | CYP1A2CYP2D6CYP2C19F10PRSS1 | |
| SCHEMBL2986476 | 0.90 | CYP1A2 (0.39) | CYP1A2CYP2D6CYP2C19F10PRSS1 | |
| Hydrochloric Acid SCHEMBL6942078 | 0.89 | CYP1A2 (0.38) | CYP1A2CYP2D6CYP2C19F10PRSS1 | |
| SCHEMBL6942676 | 0.88 | HPN (0.36) | CYP1A2CYP2D6CYP2C19F10PRSS1 | |
| SCHEMBL6939396 | 0.88 | CYP1A2 (0.38) | CYP1A2CYP2D6CYP2C19F10PRSS1 | |
| Hydrochloric Acid SCHEMBL7071388 | 0.88 | CYP1A2 (0.37) | CYP1A2CYP2D6CYP2C19F10PRSS1 | |
| SCHEMBL7563517 | 0.88 | CYP1A2 (0.37) | CYP1A2CYP2D6CYP2C19F10PRSS1 | |
| Hydrochloric Acid SCHEMBL7561338 | 0.87 | CYP1A2 (0.37) | CYP1A2CYP2D6CYP2C19F10PRSS1 | |
| Hydrochloric Acid SCHEMBL7561554 | 0.86 | GRIA2 (0.38) | CYP1A2CYP2D6CYP2C19F10PRSS1 | |
| Hydrochloric Acid SCHEMBL7562132 | 0.79 | F10 (0.36) | F10PRSS1DDR1EPHX2PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090075949-A1 | Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases | EISERT WOLFGANG | 2009-03-19 | — | — | US | claimed |
| US-20100184729-A1 | New Pharmaceutical Compositions for Treatment of Thrombosis | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-22 | — | — | US | disclosed |
| US-20090075949-A1 | Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases | EISERT WOLFGANG | 2009-03-19 | — | — | US | disclosed |
| US-20090048173-A1 | Use Of Dipyridamole For Treatment Of Resistance To Platelet Inhibitors | EISERT WOLFGANG | 2009-02-19 | — | — | US | disclosed |
| EP-1747016-A2 | USE OF DIPYRIDAMOLE FOR TREATMENT OF RESISTANCE TO PLATELET INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2007-01-31 | — | — | EP | disclosed |
| US-20060222640-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF THROMBOSIS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-10-05 | — | — | US | disclosed |
| WO-2005113006-A2 | USE OF DIPYRIDAMOLE FOR TREATMENT OF RESISTANCE TO PLATELET INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-01 | — | — | WO | disclosed |
| US-20020183519-A1 | Antithrombotic carboxylic acid amides | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048173-A1 | Use Of Dipyridamole For Treatment Of Resistance To Platelet Inhibitors | ANXA5, F5, ANXA3 | CYP1A2 3109/4885CYP2D6 961/4885CYP2C19 609/4885 |
| US-20090075949-A1 | Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases | PEPD, PLAT, TFPI | CYP1A2 288/4885CYP2D6 114/4885CYP2C19 89/4885 |
| US-20100184729-A1 | New Pharmaceutical Compositions for Treatment of Thrombosis | PROC, F12, SERPINC1 | CYP1A2 1807/4885CYP2D6 2523/4885CYP2C19 1143/4885 |
| US-20020183519-A1 | Antithrombotic carboxylic acid amides | SERPINC1, TFPI, F2 | CYP1A2 176/4885CYP2D6 1073/4885CYP2C19 273/4885 |
| US-20060222640-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF THROMBOSIS | PROC, F12, SERPINC1 | CYP1A2 1807/4885CYP2D6 2523/4885CYP2C19 1143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.